Group 1 - The company, Beilu Pharmaceutical, announced that its subsidiary, Zhejiang Haichang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing application of Iopamidol [1] - Iopamidol is a low-osmolar, non-ionic water-soluble contrast agent widely used in CT enhancement imaging and vascular imaging [1] - Compared to traditional high-osmolar contrast agents, Iopamidol places a lower burden on patients' kidneys and cardiovascular systems, making it particularly suitable for patients with renal impairment and those at high risk [1] Group 2 - Due to its excellent imaging effects and lower side effects, Iopamidol has become one of the preferred contrast agents in clinical settings [1]

碘美普尔为对比剂碘美普尔注射液的原料药，作为一种低渗透压、非离子型水溶性造影剂，碘美普尔注 射液被广泛应用于CT增强成像和血管造影。与传统的高渗透压造影剂相比，它对患者的肾脏和心血管 系统负担较小，尤其适合肾功能不全和高风险患者。由于其良好的显影效果和较低的副作用，已成为临 床上优先选择的造影剂之一。 人民财讯8月12日电，北陆药业（300016）8月12日晚间公告，近日，公司控股子公司浙江海昌药业股份 有限公司(简称"海昌药业")收到国家药监局核准签发的碘美普尔《化学原料药上市申请批准通知书》。 ...

格隆汇8月12日丨北陆药业(300016.SZ)公布，近日，北京北陆药业股份有限公司控股子公司浙江海昌药 业股份有限公司(简称"海昌药业")收到国家药品监督管理局核准签发的碘美普尔《化学原料药上市申请 批准通知书》。 碘美普尔为对比剂碘美普尔注射液的原料药，作为一种低渗透压、非离子型水溶性造影剂，碘美普尔注 射液被广泛应用于CT增强成像和血管造影。 ...